Galactica Biotech employs advanced analytical methods, particularly leveraging Machine Learning, to innovate in drug discovery and development. The company focuses on drug repurposing and repositioning, aiming to identify new applications for existing molecules, which can lead to the generation of additional intellectual property. Their virtual screening process, enhanced by Machine Learning, allows for the prioritization of molecules from various datasets, while their binding site identification technology helps analyze potential new targets for therapeutic intervention. This approach not only accelerates the drug discovery process but also aims to reduce the associated costs and risks for pharmaceutical companies.

The company's mission is to set new standards in the pharmaceutical industry by utilizing specialized knowledge to enhance drug value and contribute to public health. Galactica Biotech is actively researching and developing a pipeline of therapeutic molecules targeting both major and orphan diseases. Their commitment to innovation has been recognized by an international panel of experts from the European Commission, which awarded them a Seal of Excellence for their high-quality project proposal. This recognition underscores their dedication to excellence, impact, and efficient implementation in the field of drug discovery.

Ireland

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies.

Our Mission
With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. 




Galactica Biotech

Company Details